Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

This study has been completed.

Study NCT00083720 Information provided by ImClone LLC

First Received: May 28, 2004 Last Updated: November 2, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Colorectal Neoplasms
Metastases
Neoplasm

Additional conditions recognized in this trial

Neoplasm Metastasis
Neoplasms

More general conditions related to this trial

Interventions listed in this trial

cetuximab

More general drug interventions related to this trial

Sponsors listed in this trial

ImClone LLC
Bristol-Myers Squibb